SCHEMBL3738852

SCHEMBL3738852

CC(N)c1cccc2cc[nH]c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.52
PDPK1 O15530 1/20 0.44
BCHE P06276 3/20 0.42
KEAP1 Q14145 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
NFKB1 P19838 1/20 0.41
PNMT P11086 1/20 0.41
NR3C1 P04150 1/20 0.41
PGR P06401 1/20 0.41
NR3C2 P08235 1/20 0.41
AR P10275 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
REN P00797 2/20 0.37
BACE1 P56817 1/20 0.36
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29783549 1.00 AHR (0.52) AHRPDPK1BCHEKEAP1CYP1A2
SCHEMBL2611040 0.84 AHR (0.50) AHRPDPK1BCHEKEAP1CYP1A2
SCHEMBL2260871 0.81 AHR (0.47) AHRPDPK1BCHEKEAP1CYP1A2
SCHEMBL1251800 0.78 AHR (0.44) AHRPDPK1BCHEKEAP1CYP2D6
SCHEMBL3794702 0.78 TSHR (0.44) AHRPDPK1BCHEKEAP1NR3C1
SCHEMBL17871986 0.77 AHR (0.43) AHRPDPK1BCHEKEAP1NR3C1
SCHEMBL25474389 0.74 BCHE (0.43) AHRPDPK1BCHEKEAP1CYP2D6
SCHEMBL5154962 0.74 NR3C1 (0.46) AHRPDPK1BCHEKEAP1NR3C1
SCHEMBL6029505 0.73 AHR (0.43) AHRPDPK1BCHEKEAP1NR3C1
SCHEMBL22559186 0.73 CA12 (0.51) CYP1A2CYP3A4CYP2D6NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166598-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-05-23 US disclosed
WO-2022169891-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2022-08-11 WO disclosed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed
CN-101516360-A Substituted acetylenic compounds useful for the treatment of diseases LEO PHARMA AS (DK) 2009-08-26 CN disclosed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R AHR 1787/4885PDPK1 4055/4885BCHE 375/4885
US-20240166598-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME SARS1, ACE, PLPBP AHR 2275/4885PDPK1 2835/4885BCHE 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.